Huang Shih-Min, McCance D J
Department of Microbiology and Immunology. The Cancer Center, University of Rochester, Rochester, New York 14642, USA.
J Virol. 2002 Sep;76(17):8710-21. doi: 10.1128/jvi.76.17.8710-8721.2002.
Previously, we reported that human papillomavirus (HPV) type 16 E6 binds to C/H1, C/H3, and the C-terminal domains of coactivators p300 and CBP, causing the modulation of the transcription of certain genes controlled by NF-kappaB (p65 or relA) and p53. To establish the biological significance of these observations, we have focused on the transcriptional regulation of interleukin-8 (IL-8), a potent chemoattractant for T lymphocytes and neutrophils, which is also essential for the initiation of the local immune response. The IL-8 promoter is regulated by NF-kappaB/p65 in response to tumor necrosis factor alpha and requires the cooperation of the coactivators CBP/p300 and steroid receptor coactivator 1 (SRC-1) and the p300/CBP-associated factor (P/CAF) for optimal activation. Here we report that, in the presence of HPV-16 E6, the promoter activity of IL-8 was repressed. Moreover, from the mutational analysis of the IL-8 promoter, we found that E6 down-regulates the IL-8 promoter activity through the NF-kappaB/p65 binding site. This inhibition appears to result from the ability of HPV-16 E6 to compete with NF-kappaB/p65 and SRC-1 for binding to the N terminus and C terminus of CBP, respectively. Reporter data also showed that E7 represses IL-8 promoter activity, though to a lesser extent than E6 but, like E6, the repression by E7 is through the NF-kappaB/p65 binding site. E7 was shown for the first time to bind to P/CAF, and the binding was necessary for the down regulation of the IL-8 promoter. E6 and E7 together inhibited transcription of the IL-8 promoter to a greater extent than either alone. Finally, by RNase protection assay, we showed that the synthesis of endogenous IL-8 mRNA was repressed in keratinocytes stably expressing E6 and E7. Taken together, the results provide evidence that E6 and E7 can cooperatively disrupt IL-8 transcription through disruption of transcriptional active complexes, and this may have important consequences for immune responses in infected hosts.
此前,我们报道过16型人乳头瘤病毒(HPV)E6蛋白可与共激活因子p300和CBP的C/H1、C/H3及C末端结构域结合,从而调控某些由核因子-κB(p65或relA)和p53控制的基因转录。为确定这些发现的生物学意义,我们重点研究了白细胞介素-8(IL-8)的转录调控,IL-8是T淋巴细胞和中性粒细胞的一种强效趋化因子,对局部免疫反应的启动也至关重要。IL-8启动子受肿瘤坏死因子α刺激,由核因子-κB/p65调控,且需要共激活因子CBP/p300、类固醇受体共激活因子1(SRC-1)和p300/CBP相关因子(P/CAF)协同作用以实现最佳激活。在此我们报道,在存在HPV-16 E6的情况下,IL-8的启动子活性受到抑制。此外,通过对IL-8启动子的突变分析,我们发现E6通过核因子-κB/p65结合位点下调IL-8启动子活性。这种抑制作用似乎源于HPV-16 E6分别与核因子-κB/p65和SRC-1竞争结合CBP的N末端和C末端的能力。报告基因数据还显示,E7也抑制IL-8启动子活性,尽管程度小于E6,但与E6一样,E7的抑制作用也是通过核因子-κB/p65结合位点。首次证明E7可与P/CAF结合,且这种结合对于IL-8启动子的下调是必需的。E6和E7共同作用时对IL-8启动子转录的抑制作用比单独作用时更强。最后,通过核糖核酸酶保护试验,我们表明在稳定表达E